Patent Foramen Ovale Closure Device Market Size, Share & Trends Analysis | Global | 2026-2032

Global Patent Foramen Ovale Closure Device Market Report to 2032

The global patent foramen ovale closure device market was valued at $497.9 million in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 5.5%, reaching $724.7 million by 2032.

This report covers the global market for patent foramen ovale (PFO) closure devices, including devices used to treat a defect in the septum between the two atrial chambers of the heart.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by minimally invasive catheter-based procedures, improved diagnosis of clinically relevant PFOs, and increased awareness of the link between PFO and cryptogenic stroke. However, limited long-term clinical data, low diagnosis rates, and future left atrial access challenges continue to limit stronger adoption.

Market Overview

The global patent foramen ovale closure device market includes devices used to close a PFO, a small opening between the right and left atria of the heart. While many PFOs are asymptomatic, some are clinically relevant, especially in patients evaluated after cryptogenic ischemic stroke or other embolic events.

PFO closure devices are delivered through a minimally invasive catheter-based approach. These products allow specialists to close the defect without open surgery, reducing procedural trauma, hospital stay, and recovery time.

Globally, increased awareness of the association between PFO and cryptogenic stroke has improved diagnostic rates, especially in adult patient populations. Improved diagnostic pathways in stroke workups are expected to support continued growth in treated cases.

Advances in imaging modalities, including transesophageal echocardiography and transcranial Doppler screening, have improved identification of clinically relevant PFOs. While routine screening of infants for PFO is not standard practice, better diagnosis during stroke evaluation is expected to sustain demand for PFO closure devices over the forecast period.

Market Drivers

Minimally Invasive Procedures

Minimally invasive treatment is the main driver of the PFO closure device market. PFO procedures were traditionally performed through open surgery, which required more invasive access and longer recovery.

PFO occluders allow specialists to perform closure through a catheter-based procedure. This approach is favored because it can reduce pain, shorten hospital stays, and limit the burden of recovery for patients.

Minimally invasive procedures also make treatment possible for patients who may be too sick or high-risk to undergo open surgery. This expands the practical treatment population and supports continued adoption of PFO closure devices.

Increased Awareness of PFO and Cryptogenic Stroke

Awareness of the relationship between PFO and cryptogenic stroke has improved in many global markets. This is especially important because many patients with PFO remain asymptomatic until the defect is identified during a stroke-related workup.

As more clinicians consider PFO during evaluation of unexplained ischemic stroke, diagnosis rates are expected to improve. This supports a larger treated patient pool and increases procedural demand.

The treatable PFO population remains concentrated among patients who have experienced cryptogenic ischemic stroke or related embolic events. As awareness grows among neurologists, cardiologists, and stroke teams, more patients may be referred for evaluation and potential closure.

Improved Diagnostic Pathways

Advances in diagnostic pathways are supporting growth in the PFO closure device market. Imaging modalities such as transesophageal echocardiography and transcranial Doppler screening have improved identification of clinically relevant PFOs.

These tools help clinicians evaluate whether a PFO may be related to a patient's stroke history or embolic risk. Better diagnostic confidence can support treatment decisions and referral patterns.

Although general population screening remains limited, improved stroke workups are expected to increase diagnosis of patients most likely to benefit from closure. This supports steady growth in treated cases through 2032.

Market Limiters

Lack of Clinical Data

Limited long-term clinical data remains a key restraint in the PFO closure device market. The use of PFO closure devices to treat stroke patients is relatively well established in the short term, with trials showing reduced likelihood of future strokes compared with anticoagulation therapy alone.

However, debate continues around long-term outcomes from recent trials, including the Gore REDUCE, CLOSE, and RESPECT trials. This lack of full confidence in long-term outcomes may limit adoption over the forecast period.

There is also limited clinical data supporting PFO closure for migraine treatment. The MIST, PRIMA, and PREMIUM trials showed negative results, although the PREMIUM trial did show a reduction in migraine days after PFO closure. Until stronger data is available, approval and use for migraine-related indications will remain limited.

Low Diagnosis Rate for Patients with PFO

Most individuals with a PFO remain asymptomatic. As a result, a large proportion of cases go undiagnosed and untreated.

As of 2025, the treatable PFO population remains mainly concentrated among patients who have experienced cryptogenic ischemic stroke or other embolic events. PFOs are most often identified during post-stroke diagnostic evaluations.

Despite improved awareness and better imaging tools, the overall diagnosis and treatment rate remains low compared with the estimated prevalence of PFO in the general population. This limits market expansion because many patients with PFO are never evaluated for closure.

Future Access Challenges

Future access to the left atrium is another limiter for the PFO closure device market. As left-sided procedures grow, including percutaneous mitral valve interventions and left atrial appendage closure, physicians may need future access through the atrial septum.

A PFO closure device can make future access to the left atrium more challenging. This may influence physician decision-making, especially in patients who could require future structural heart or electrophysiology procedures.

Until a bioresorbable PFO closure device is available on the open market, this concern may limit some procedures. Clinicians may weigh the benefit of closure against the possibility of future access needs.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
• Device scope: The report covers patent foramen ovale closure devices used to treat a defect in the septum between the two atrial chambers of the heart.

Markets Covered and Segmentation

Patent Foramen Ovale Closure Device Market

The report covers the global patent foramen ovale closure device market as a dedicated cardiac surgery and structural heart device segment.

PFO closure devices are used to close an opening between the atrial chambers of the heart. These devices are placed through a catheter-based procedure and are most commonly used in selected patients with cryptogenic ischemic stroke or embolic risk.

The market is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

The report evaluates demand based on diagnosis rates, stroke workup pathways, minimally invasive procedure adoption, clinical evidence, physician preference, reimbursement conditions, and future access considerations.

This structure helps manufacturers, investors, and strategy teams understand how clinical use cases, diagnostic pathways, long-term evidence, and competitive positioning are shaping the global PFO closure device market.

Competitive Analysis

Abbott was the leading competitor in the global PFO closure device market in 2025. The company offers the Amplatzer(TM) PFO Occluder.

Abbott's early presence in the market has supported its leadership position. The Amplatzer(TM) platform is well established and benefits from physician familiarity, broad market presence, and continued use in catheter-based PFO closure procedures.

Gore was the second-leading competitor in the global PFO closure device market in 2025. The company offers the Gore(R) Cardioform Septal Occluder.

The Gore(R) Cardioform Septal Occluder is approved for atrial septal defect and PFO closure in Europe. The device supports Gore's position in structural heart closure, although regional companies limit the company's expansion in some global markets.

The competitive landscape is led by established companies with proven occluder technologies, physician familiarity, and international distribution. However, global expansion depends on regional approvals, clinical evidence, local competitors, and adoption patterns within stroke and structural heart programs.

Technology and Practice Trends

Catheter-Based Closure

Catheter-based PFO closure remains the core practice trend in the market. These procedures allow closure without open surgery, reducing procedural trauma and recovery burden.

This minimally invasive approach is central to continued adoption.

Stroke Workup Integration

PFO diagnosis is increasingly tied to cryptogenic stroke workups. When patients experience unexplained ischemic stroke, clinicians may evaluate whether a PFO could be involved.

This pathway is expected to remain the main source of treated PFO patients.

Improved Imaging

Transesophageal echocardiography and transcranial Doppler screening are improving detection of clinically relevant PFOs.

Better imaging supports more accurate diagnosis and helps clinicians identify patients who may benefit from closure.

Selective Patient Treatment

Because many PFOs are asymptomatic, treatment is selective. Closure is most relevant for patients with stroke history or embolic events where the PFO is believed to be clinically meaningful.

This keeps the treatable population smaller than the estimated total PFO prevalence.

Long-Term Outcomes Review

Long-term outcomes remain under review. Physicians and payers continue to evaluate trial data to understand which patients benefit most from closure.

Greater confidence in long-term outcomes would support broader adoption.

Future Left Atrial Access Planning

Future access to the left atrium is becoming more important as left-sided procedures increase. PFO closure may complicate later access for mitral, LAA, or ablation procedures.

This trend may support future interest in bioresorbable closure technologies.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global patent foramen ovale closure device market today, and how much is it expected to grow through 2032?
• How are unit sales, procedure numbers, ASPs, and market values changing over time?
• What role do PFO closure devices play in treating atrial septal defects linked to embolic risk?
• How is awareness of PFO and cryptogenic stroke affecting diagnosis and treatment?
• How are transesophageal echocardiography and transcranial Doppler screening improving patient identification?
• Why are minimally invasive catheter-based procedures driving adoption?
• What long-term clinical data questions still limit broader use?
• Why does the low diagnosis rate for asymptomatic PFO patients constrain the market?
• How could future left atrial access needs affect PFO closure decisions?
• Which companies lead the global PFO closure device market?

The Global Patent Foramen Ovale Closure Device Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand structural heart closure trends, and support commercial planning in the global PFO closure device market.